Literature DB >> 16376804

Bone and joint disease associated with primary immune deficiencies.

Christelle Sordet1, Alain Cantagrel, Thierry Schaeverbeke, Jean Sibilia.   

Abstract

Primary immune deficiencies (PIDs) are characterized by functional and/or quantitative abnormalities of one or more immune system components. Several bone and joint abnormalities can occur in patients with PID, with arthritis being the most common. Joint manifestations, of which arthritis is the most common, occur chiefly in humoral PIDs (agammaglobulinemia, common variable immunodeficiency, hyper-IgM syndromes, and IgA deficiency) and occasionally in other PIDs (chronic granulomatous disease and Wiskott-Aldrich syndrome). Monoarthritis or oligoarthritis is the usual pattern, although polyarthritis may occur, occasionally with nodules suggesting rheumatoid arthritis. Arthritis in patients with PID is usually infectious in nature, the most common causative organism being Mycoplasma, followed by Staphylococcus, Streptococcus, and Haemophilus. These bacteria can induce not only synovial infections, but also aseptic arthritogenic inflammatory responses. Arthritis having no demonstrable relation to chronic infection has been reported also and ascribed to dysimmunity-driven mechanisms that exhibit a number of specific features. Bone lesions are far less common and usually due to infections complicating humoral PID. Distinctive bone manifestations occur in a number of rare PIDs (e.g., hyper-IgE syndrome and Di George syndrome) and in syndromes characterized by spondyloepiphyseal dysplasia. Familiarity with PID syndromes both enhances the diagnostic capabilities of physicians and provides insight into the pathophysiology of bone and joint abnormalities associated with immune dysfunction. In children and occasionally in adults, a combination of bone and/or joint manifestations and hypogammaglobulinemia may indicate PID. When there is no evidence of lymphoproliferative disease, infection, or iatrogenic complications, investigations for PID should be obtained. PID-related arthritis is a unique model for studying the pathogenesis of presumably postinfectious arthritis and of inflammatory joint diseases including rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376804     DOI: 10.1016/j.jbspin.2004.07.012

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  9 in total

1.  Arthritis as a presenting symptom in a hypogammaglobulinemic patient with thymectomy.

Authors:  Omür Ardeniz; Sezgin Vatansever; Uğur Musabak; Kenan Aksu; Aytül Sin; Ali Kokuludağ
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

Review 2.  Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

Authors:  Ewa Więsik-Szewczyk; Aleksandra Kucharczyk; Katarzyna Świerkocka; Elżbieta Rutkowska; Karina Jahnz-Różyk
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

Review 3.  Rheumatologic manifestations of primary immunodeficiency diseases.

Authors:  V R Dimitriades; R Sorensen
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

Review 4.  Therapeutic management of primary immunodeficiency in older patients.

Authors:  Nisha Verma; Anthony Thaventhiran; Benjamin Gathmann; James Thaventhiran; Bodo Grimbacher
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

Review 5.  Autoimmunity in common variable immunodeficiency.

Authors:  Susana Lopes-da-Silva; Luiz Vicente Rizzo
Journal:  J Clin Immunol       Date:  2008-04-29       Impact factor: 8.317

Review 6.  Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.

Authors:  P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

7.  Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.

Authors:  Philip Wood
Journal:  Ther Clin Risk Manag       Date:  2012-04-02       Impact factor: 2.423

8.  Brain Abscess and Keratoacanthoma Suggestive of Hyper IgE Syndrome.

Authors:  Soheyla Alyasin; Reza Amin; Alireza Teymoori; Hamidreza Houshmand; Gholamreza Houshmand; Mohammad Bahadoram
Journal:  Case Reports Immunol       Date:  2015-04-28

Review 9.  Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice.

Authors:  Beatriz Tavares Costa-Carvalho; Anete Sevciovic Grumach; José Luis Franco; Francisco Javier Espinosa-Rosales; Lily E Leiva; Alejandra King; Oscar Porras; Liliana Bezrodnik; Mathias Oleastro; Ricardo U Sorensen; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2013-11-16       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.